Newly Diagnosed

Oncology·MeSH: Ovarian Neoplasms

36 drugs in development·22 companies·1 clinical trial

Drug Pipeline by Phase

Approved(12)

Drug	Company
imatinib	Amneal Pharmaceuticals, Inc. (AMRX)
imatinib	SUNSET ISLAND GROUP (SUN)
imatinib	Aptinyx Inc. (APTX)
imatinib	Mylan II B.V. (MYL)
imatinib	Teva Pharmaceutical Industries Limited (TEVA)
imatinib	DR REDDYS LABORATORIES LTD (RDY)
imkeldi	CG Oncology, Inc. (CGON)
nilotinib	DR REDDYS LABORATORIES LTD (RDY)
nilotinib	Aptinyx Inc. (APTX)
nilotinib	Mersana Therapeutics, Inc. (MRSN)
thalomid	CELGENE CORP /DE/ (CELG)
venetoclax	DR REDDYS LABORATORIES LTD (RDY)

Phase 3(4)

Drug	Company
CAN-2409	Candel Therapeutics, Inc. (CADL)
ict-107	EOM Pharmaceutical Holdings, Inc. (IMUC)
Leucovorin Calcium	Assertio Holdings, Inc. (ASRT)
low-intensity chemotherapy regimen	AMGEN INC (AMGN)

Phase 2(9)

Drug	Company
Bortezomib	FATE THERAPEUTICS INC (FATE)
Bortezomib	Coeptis Therapeutics Holdings Inc. (COEP)
CLD-101 (NeuroNova™)	Calidi Biotherapeutics Inc. (CLDI)
Daratumumab	FATE THERAPEUTICS INC (FATE)
Daratumumab	Coeptis Therapeutics Holdings Inc. (COEP)
Gilteritinib	Crinetics Pharmaceuticals, Inc. (CRNX)
H1 receptor antagonist	Merus N.V. (MRUS)
H2 receptor antagonist	Merus N.V. (MRUS)
inb-400	IN8BIO, INC. (INAB)

Phase 1(10)

Drug	Company
[177lu]lu-neob	Novartis AG (NVS)
[68ga]ga-neob	Novartis AG (NVS)
blinatumomab	AMGEN INC (AMGN)
CELZ-201 CREATE-1	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
Hyper-CVAD	Merus N.V. (MRUS)
immunization	Black Diamond Therapeutics, Inc. (BDTX)
inb-200	IN8BIO, INC. (INAB)
Ixazomib	FATE THERAPEUTICS INC (FATE)
Mini-hyper-CVD	Merus N.V. (MRUS)
TAK-079	Merus N.V. (MRUS)

Phase 1/Phase 2(1)

Drug	Company
Type I Diabetes (CELZ-201 CREATE-1)	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)

BioSniper tracks 36 drugs in development for Newly Diagnosed across 22 companies.

There are 1 clinical trial targeting Newly Diagnosed tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.